| Document |
Document Title |
|
WO/2020/135715A1 |
Disclosed is a compound represented by Formula (I), optical isomers thereof, pharmaceutically acceptable salts thereof, and an application of the compound as a STING agonist. (I)
|
|
WO/2020/136170A2 |
Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with acetal or thiocarbamate 3ʹ-OH blocking groups. Also provided herein are methods to prepare such nucleotide and nucleoside molecules, and the uses o...
|
|
WO/2020/139871A1 |
Methods, systems, compositions, and devices for the manufacturing of high-quality building blocks, such as polynucleotides, are described herein. Processes described herein provide for efficient washing of residual reagents, solvents, or...
|
|
WO/2020/139962A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For examp...
|
|
WO/2020/139960A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed. For example, inhibitors of galectin-3 are described an...
|
|
WO/2020/131578A2 |
The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have ...
|
|
WO/2020/131649A1 |
The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4'- Ethynyl-2-fluoro-2'-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the...
|
|
WO/2020/127461A1 |
The present invention relates to a stabilized amorphous form of a compound of formula (I) as well as compositions for oral administration comprising the compound of formula (I) in a therapeutically effective amount.
|
|
WO/2020/128469A1 |
The present invention generally relates to a novel process for the preparation of 8-chloroadenosine derivatives, and particularly NUC-9701(8-chloroadenosine-5'-O- [naphthyl(benzyloxy-L-alaninyl)] phosphate) an anticancer ProTide of 8-chl...
|
|
WO/2020/131759A1 |
The present disclosure provides 3' protected nucleotides, including those 3' protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3' protected nucleotides are also disclosed, such as th...
|
|
WO/2020/123772A1 |
Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form ...
|
|
WO/2020/123488A1 |
The present disclosure provides crystalline Form II of nicotinic acid riboside, crystalline Form II of nicotinic acid riboside triacetate, and methods of preparation thereof. In an embodiment, the present disclosure relates to crystallin...
|
|
WO/2020/122547A1 |
The present invention relates to a nicotinamide riboside derivative conjugated to a fatty alcohol, and a wrinkle reducing or anti-aging composition comprising same. A nicotinamide riboside derivative conjugated to a fatty alcohol accordi...
|
|
WO/2020/117623A1 |
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...
|
|
WO/2020/117625A1 |
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...
|
|
WO/2020/118139A1 |
Disclosed are compounds of the formulas (I), (II), and (II): which are A1 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein Y, R1‑R6, R10‑R15, and R20â...
|
|
WO/2020/117624A1 |
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...
|
|
WO/2020/108343A1 |
(I) An oral pharmaceutical composition containing a 4'-thionucleoside compound of formula (I), a capsule and a product containing same, and a preparation method therefor and the use thereof. The oral pharmaceutical composition has a good...
|
|
WO/2020/104335A1 |
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...
|
|
WO/2020/103929A1 |
Disclosed is an oligonucleotide and a prodrug thereof, and in particular, disclosed are: a compound shown by formula I, a tautomer thereof, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method, a pharmaceuti...
|
|
WO/2020/103916A1 |
Provided is a separation and purification method for uridine triphosphate. The separation and purification method comprises the following steps: 1) loading: filtering crude uridine triphosphate and then loading same into a chromatography...
|
|
WO/2020/104492A1 |
The present invention relates to a method for preparing stereodefined phosphorothioate oligonucleotides, especially locked stereodefined phosphorothioate oligonucleotides with a high yield, using pyridinium acidic salts as a coupling act...
|
|
WO/2020/107013A1 |
The disclosure includes compounds of Formula (I): wherein R1, R2, and R3, are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.
|
|
WO/2020/102980A1 |
Proposed is a preparation method for a nucleotide for sequencing, i.e. a preparation method for a compound represented by formula (I), comprising (1) performing a first nucleophilic substitution reaction on a compound represented by form...
|
|
WO/2020/100826A1 |
The present invention provides a novel crosslinked artificial nucleic acid and an oligomer that includes the same as a monomer. More specifically, the present invention provides a compound represented by general formula (I) (the symbols ...
|
|
WO/2020/102326A1 |
The present application provides methods for determining the level of NAD in a patient, including a whole blood sample from a patient. In addition, methods of increasing NAD levels in combination with determining the NAD level in a patie...
|
|
WO/2020/085720A1 |
The present invention relates to a process for simultaneously preparing a lactic acid bacteria nucleotide and a low-molecular weight functional biomaterial having utility in industries related to skincare and cosmetics, and more specific...
|
|
WO/2020/086366A1 |
The present disclosure provides methods for separating nucleic acids in a sample based on the length of the nucleic acids using a capillary electrophoresis device with formamide as a denaturing agent and a non-aqueous separation matrix c...
|
|
WO/2020/086834A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of using the same for the sequencing of a nucleic acid.
|
|
WO/2020/078807A1 |
The present invention relates to a prodrug compound of the general formula I or II. The prodrug compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3...
|
|
WO/2020/078808A1 |
The present invention relates to a compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in ...
|
|
WO/2020/081690A1 |
A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.
|
|
WO/2020/078000A1 |
1,3-disubstituted-2H-imidazolyl-2-carbene is a common type of azacyclocarbene, which may be used in a plurality of fields, comprising catalyzing organic reactions, acting as a transition metal ligand, and acting as a supporting ligand in...
|
|
WO/2020/073274A1 |
Provided is a method for determining the sequence of a target single-chain polynucleotide, which method comprises monitoring the successive incorporation of nucleotides complementary to the target single-chain polynucleotide, wherein the...
|
|
WO/2020/074004A1 |
Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compoung acting as a STING agonist.
|
|
WO/2020/072497A1 |
The invention provides a compound of formula (I): (I) wherein R is methyl or ethyl. The invention also provides a process for the preparation of the compound. The invention further provides a method for increasing cell NAD+ production or...
|
|
WO/2020/073026A1 |
This disclosure provides a method of synthesis of 4'-thioribose NAD+ and analogues thereof, using an efficient chemoenzymatic approach. Also provided are methods of inhibiting the CD38 enzyme and compounds including 4'-thioribose NAD+ an...
|
|
WO/2020/068657A1 |
Halogenated analogs of 5-aza-2'-deoxycytidine, such as halogenated analogs of 5-aza-4'-thio-2'-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated an...
|
|
WO/2020/069424A1 |
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...
|
|
WO/2020/056713A1 |
A method for preparing high-purity NAD, comprising: adjusting a pH value to 6.0-8.0, removing insoluble substances, heating to 35 ± 1°C, adding ethanol, cooling to 6 ± 0.5°C, crystallizing, filtering, heating a filtrate to 25-30°C, ...
|
|
WO/2020/057546A1 |
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...
|
|
WO/2020/054444A1 |
[Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the for...
|
|
WO/2020/055753A1 |
The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or...
|
|
WO/2020/051686A1 |
CD73 (also known as ecto-5 ' -nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...
|
|
WO/2020/050411A1 |
The present invention provides a method for producing a glycoside compound represented by general formula (3), said glycoside compound enabling the synthesis of a desired compound (an amidite) with high purity. This method comprises a st...
|
|
WO/2020/045628A1 |
The present invention addresses the problem of providing a nucleic acid analog, and a pharmaceutical composition, an anti-hepatitis virus agent and a preventive or therapeutic agent for a hepatitis virus-related disease each comprising a...
|
|
WO/2020/047082A1 |
This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents fo...
|
|
WO/2020/042729A1 |
Disclosed are a 6-disulfide-substituted-2'-deoxyguanosine compound and a preparation method therefor and a use thereof in an anti-tumor drug. Using 2'-deoxyguanosine as a structure mother nucleus, the present invention designs and synthe...
|
|
WO/2020/041051A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
|
WO/2020/041050A1 |
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.
|
